BioMarin to Acquire Amicus Therapeutics for $4.8 Billion — A Strategic Push to Tighten Rare‑Disease Leadership
BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics in an all‑cash deal valued at approximately $4.8 billion
Category: Healthcare and Life Sciences
Philips Bets On AI To See Inside Arteries With SpectraWAVE Buy
Royal Philips (NYSE: PHG), a global leader in medical technology, has agreed to acquire SpectraWAVE, Inc., a Massachusetts-based innovator in **AI-powered intravascular imaging**, to bolster its...
Nippon Life’s Strategic Leap: Pursuing a Medical‑data Platform in a Milestone Buy
Nippon Life Insurance Co. is pursuing an acquisition of a Japanese medical‑data firm, marking what executives describe as a strategic milestone as the insurer shifts from traditional asset...
Japanese Pharmas Expand Cross-Border M&A Footprint in US and EU Amid Domestic Market Stagnation
Japanese pharmaceutical companies are increasingly pursuing mergers and acquisitions (M&A) beyond their domestic borders, targeting strategic assets in the United States and Europe to drive growth...
Teleflex Divests Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion
Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, announced a strategic divestiture of its Acute Care, Interventional Urology, and Original Equipment Manufacturing (OEM)...
Mirum Pharmaceuticals Expands Rare Liver Disease Portfolio with $820 Million Bluejay Therapeutics Acquisition
Mirum Pharmaceuticals (Nasdaq: MIRM), a leading rare disease biopharma, announced a definitive agreement to acquire Bluejay Therapeutics, a privately held biotech focused on viral and liver...
Biocon’s Strategic Integration of Biocon Biologics: A $5.5 Billion Transformation Reshaping Global Biopharmaceutical Leadership
Biotechnology major Biocon has announced a strategic corporate action to fully integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary into Biocon Limited, valuing the biologics unit...
AbbVie’s $1.2 Billion Psychedelic Bet Signals Strategic Shift as Retail Investors Weigh Post-Humira Growth
AbbVie's recent acquisition of Gilgamesh Pharmaceuticals' psychedelic depression treatment for up to $1.2 billion represents a pivotal moment in the pharmaceutical giant's post-Humira...
Hims & Hers’ Strategic Expansion into Canada: Leveraging ZAVA Acquisition and Generic Semaglutide for Market Disruption
Hims & Hers Health's planned 2026 Canadian expansion represents a pivotal strategic shift, combining its recent acquisition of European digital health platform ZAVA with the anticipated launch of...
Merck’s $10 Billion Verona Pharma Acquisition: Strategic Masterstroke in the COPD Therapeutics Revolution
The pharmaceutical industry witnessed a landmark transaction on July 9, 2025, as Merck & Co. announced its definitive agreement to acquire Verona Pharma for approximately $10 billion, securing...